iCAD Wins Three-System Public Bid with Leading Cancer Organization in Spain, Expanding European Access to Innovative Cancer Treatments with the Xoft System
Two additional Spanish centers
announce adoption of the Xoft System, totaling seven installations across four
major regions in Spain
Internationally-recognized
institutions strengthen portfolio of comprehensive cancer care solutions with iCAD’s
state-of-the-art electronic brachytherapy technology
Nashua,
N.H. – April 15, 2019
– iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today announced that the Catalan Institute of
Oncology (ICO), a leading, multi-center cancer organization in Spain, has
selected iCAD as the provider of electronic brachytherapy technology for the treatment
of early-stage breast cancer and gynecological cancers. ICO will introduce iCAD’s
Xoft® Axxent® Electronic Brachytherapy (eBx®)
System® at three hospitals located in L’Hospitalet de Llobregat, Badalona, and Girona, Spain.
In addition, New Cáceres Hospital in Cáceres and Obispo Polanco Hospital
in Teruel have also adopted the Xoft System for the treatment of early-stage
breast cancer, gynecological cancers, and non-melanoma skin cancer. The
deals were completed in partnership with Aplicaciones Tecnológicas S.A., the
distributor of the Xoft System in Spain.
With the addition of these facilities,
Xoft treatments will now be available at seven Spanish hospitals, including Hospital
Universitario Miguel Servet in Zaragoza and Hospital Clinico Universitario in
Salamanca, providing cancer treatment services in four
of the most densely populated regions of Spain: Catalonia, Aragon, Castile and
León, and Extremadura.
“We are pleased to partner with
these world-class
institutions to provide unprecedented access
to our revolutionary technology in Spain,” said Stacey Stevens, President of iCAD.
“As global adoption of the Xoft System continues to expand, we look forward to continuing
to provide patients and clinicians worldwide with our unique and versatile
platform solution offering proven benefits in treating a range of cancers.”
ICO will offer Xoft treatments at ICO L’Hospitalet – Bellvitge University
Hospital, ICO Badalona – Germans Trias i Pujol University Hospital and ICO
Girona – Doctor Josep Trueta University Hospital. With an established network
of partnerships throughout the region, ICO serves as the referral center for 60
percent of the adult population in Catalonia. Following the Comprehensive
Cancer Centre model defined by the European Organization of Cancer Institutes,
ICO takes an integrated, full-service approach to cancer care including
prevention, care, specialized training, and research. To date, it is the only organization
of its kind in Spain.
“In our thorough review of
cutting-edge radiation therapy technology available today, the Xoft System’s
distinguished versatility across a variety of clinical applications, mobility,
and unique benefits for both patients and clinicians made it the optimal
solution for our organization,” said Carles Muñoz, Technology and Physics Manager
at ICO. “The Xoft System seamlessly aligns with our mission to reduce the
impact of cancer through advanced treatments that deliver high-quality,
effective outcomes, and we are proud to offer this new option to patients in
the region.”
The Xoft System is a
proprietary electronic brachytherapy platform designed to deliver isotope-free
(non-radioactive) radiation therapy. It is FDA cleared, CE marked, and licensed
in a growing number of countries for the treatment of cancer anywhere in the
body, including early-stage breast cancer, gynecological cancers and
non-melanoma skin cancer. It uses a miniaturized x-ray source to deliver
targeted radiation directly to the cancerous site, sparing healthy tissues and
surrounding organs. The Xoft System is highly mobile and requires minimal
shielding, allowing it to be used in a variety of clinical settings and
eliminating the need for room redesign or construction investment. For
more information, please visit www.xoftinc.com.
About iCAD, Inc.
Headquartered
in Nashua, N.H., iCAD is a global medical technology leader providing
innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
About Institute of Oncology in Catalonia (ICO)
The
Catalan Institute of Oncology (ICO) is a public center working exclusively in
the field of cancer. Its approach to the disease is comprehensive, combining,
all in one organization, prevention, care, specialized training and research.
The ICO is a public company created in 1995 by the Ministry of Health of the
Government of Catalonia. It went into service a year later, operating from the
Duran i Reynals Hospital in L’Hospitalet de Llobregat. Seven years later,
in 2002, ICO Girona opened its doors, located in Doctor Josep Trueta University
Hospital, followed by ICO Badalona a year later, at the Germans Trias i Pujol
University Hospital. In 2014, it launched ICO Camp de Tarragona and Terres de
l’Ebre, in Joan XXIII Univeristy Hospital and Verge de la Cinta Hospital. Currently,
ICO is an oncology referral centre 60 percent of the adult population of
Catalonia.
“Safe
Harbor” Statement under the Private Securities Litigation Reform Act of
1995
Certain
statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited, to the
Company’s ability to defend itself in litigation matters, to achieve business
and strategic objectives, the risks of uncertainty of patent protection, the
impact of supply and manufacturing constraints or difficulties, uncertainty of
future sales levels, protection of patents and other proprietary rights, the
impact of supply and manufacturing constraints or difficulties, product market
acceptance, possible technological obsolescence of products, increased
competition, litigation and/or government regulation, changes in Medicare or
other reimbursement policies, risks relating to our existing and future debt
obligations, competitive factors, the effects of a decline in the economy or
markets served by the Company; and other risks detailed in the Company’s
filings with the Securities and Exchange Commission. The words “believe,”
“demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,”
“likely,” “seek,” and similar expressions identify forward-looking statements.
Readers are cautioned not to place undue reliance on those forward-looking
statements, which speak only as of the date the statement was made. The Company
is under no obligation to provide any updates to any information contained in
this release. For additional disclosure regarding these and other risks faced
by iCAD, please see the disclosure contained in our public filings with the
Securities and Exchange Commission, available on the Investors section of our
website at http://www.icadmed.com and
on the SEC’s website at http://www.sec.gov.
Contact:
Media Inquiries:
ARPR, on behalf of iCAD, Inc.
Paul Barren, (855) 300-8209
Investor Relations:
LifeSci Advisors, on behalf of iCAD, Inc.
Jeremy Feffer, (212) 915-2568